ASPX News
Archived Headlines
- Orphan disease biotech Versartis sets terms for $81 million IPO 03/10/14
- CNS disorders pharmaceutical Adamas files for a $69 million IPO 03/05/14
- US IPO Recap: Revance jumps 68% in ten-IPO week 02/10/14
- Auspex Pharmaceuticals prices IPO at $12, the high end of the range, and increases deal size 02/05/14
- Auspex Pharmaceuticals increases shares offered, deal size is now $66 million 02/04/14
See more
Ice Buckets and IPOs: 6 biotechs targeting CNS diseases
The ALS Association issued a press release Tuesday stating that donations in the past month have reached $89 million, including $66 million in the past...read more
Renaissance Capital's 1Q 2014 US IPO Quarterly Review
The US IPO market showed more activity than any other first quarter since 2000 as 64 companies raised $10.6 billion. That is more than double the number of IPOs in the first quarter of 2013, a year that also had the most public offerings in over a decade. IPO...read more
CNS disorders pharmaceutical Adamas Pharmaceuticals sets terms for $51 million IPO
Adamas Pharmaceuticals, which develops treatments for CNS disorders such as Parkinson's and Alzheimer's, announced terms for its IPO on Wednesday. The Emeryville, CA-based company plans to raise $51 million by offering 3.0 million shares at a price range of $16...read more
Orphan disease biotech Versartis upsizes IPO and increases range to $19 to $21
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise up to $126 million by offering 6.0 million shares at a...read more